What's new? Log in Free sign up

Edgewise Therapeutics (EWTX)

Company Profile

Company profile

Ticker

EWTX

Exchange

Website

www.edgewisetx.com

CEO

Dr. Kevin Koch Ph.D.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris • AbbVie • Bausch Health Companies ...

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

IRS number

821725586

EWTX stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$43.33

Low target

$30.00

High target

$50.00

Evercore ISI Group

Latest filings (excl ownership)

View all

Registration of securities for employees

3 Mar 25

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Departure of Directors or Certain Officers

Regulation FD Disclosure

Registration of securities for employees

Quarterly report

7 Nov 24

Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Departure of Directors or Certain Officers

Quarterly report

8 Aug 24

Latest ownership filings

View all

PERCEPTIVE ADVISORS LLC

JANUS HENDERSON GROUP PLC

Behrad Derakhshan

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Paradigm Biocapital Advisors LP

Joanne M. Donovan

Financial summary

Financial statements Chart EWTX financial data

Quarter (USD)	Dec 24	Sep 24	Jun 24	Mar 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	41.67 mm	41.67 mm	41.67 mm	41.67 mm	41.67 mm	41.67 mm
Cash burn (monthly)	1.05 mm	3.70 mm	15.18 mm	13.24 mm	8.99 mm	9.09 mm
Cash used (since last report)	2.39 mm	8.46 mm	34.67 mm	30.23 mm	20.52 mm	20.75 mm
Cash remaining	39.28 mm	33.21 mm	6.99 mm	11.43 mm	21.14 mm	20.91 mm
Runway (months of cash)	37.5	9.0	0.5	0.9	2.4	2.3

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

EWTX institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	204	180	+13.3%
Opened positions	46	54	-14.8%
Closed positions	22	16	+37.5%
Increased positions	71	57	+24.6%
Reduced positions	61	45	+35.6%

13F shares	Current	Prev Q	Change
Total value	2.63 tn	2.69 tn	-2.4%
Total shares	103.62 mm	106.04 mm	-2.3%
Total puts	231.90 k	410.00 k	-43.4%
Total calls	884.80 k	2.17 mm	-59.2%
Total put/call ratio	0.3	0.2	+38.7%

Largest owners	Shares	Value	Change
Orbimed Advisors	15.02 mm	$401.08 bn	0.0%
Ra Capital Management	8.91 mm	$237.87 bn	0.0%
BlackRock	6.48 mm	$172.99 bn	+1.3%
Baker Bros. Advisors	6.16 mm	$164.36 bn	+5.4%
Novo Holdings A/S	5.00 mm	$133.50 bn	-9.9%
JHG Janus Henderson	4.98 mm	$133.04 bn	+9.3%
Paradigm Biocapital Advisors	4.49 mm	$119.99 bn	+61.1%
Vanguard	4.47 mm	$119.26 bn	-1.1%
Cormorant Asset Management	3.41 mm	$90.95 bn	0.0%
Cormorant Global Healthcare Master Fund	2.95 mm	$0.00	0.0%

Largest transactions	Shares	Bought/sold	Change
TCG Crossover Management	0.00	-2.11 mm	EXIT
Paradigm Biocapital Advisors	4.49 mm	+1.70 mm	+61.1%
Frazier Life Sciences Management	1.27 mm	-1.56 mm	-55.1%
EcoR1 Capital	0.00	-1.25 mm	EXIT
VR Adviser	0.00	-1.00 mm	EXIT
First Light Asset Management	780.64 k	+780.64 k	NEW
Foresite Capital Management VI	585.00 k	+585.00 k	NEW
Integral Health Asset Management	550.00 k	+550.00 k	NEW
Novo Holdings A/S	5.00 mm	-549.90 k	-9.9%
Marshall Wace	29.89 k	-547.67 k	-94.8%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

EWTX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
6 Feb 25	Alan J Russell	Common Stock	Sell	Dispose S	No	Yes	30.1275	1,200	36.15 k	14,863
6 Feb 25	Alan J Russell	Common Stock	Option exercise	Acquire M	No	No	0.18	1,200	216.00	16,063
6 Feb 25	Alan J Russell	Stock Option Common Stock	Option exercise	Dispose M	No	No	0.18	1,200	216.00	1,347,565
6 Feb 25	Koch Kevin	Common Stock	Sell	Dispose S	No	Yes	31.1311	900	28.02 k	14,478
6 Feb 25	Koch Kevin	Common Stock	Option exercise	Acquire M	No	No	13.11	900	11.80 k	15,378
6 Feb 25	Koch Kevin	Stock Option Common Stock	Option exercise	Dispose M	No	No	0.18	900	162.00	41,645
5 Feb 25	Alan J Russell	Common Stock	Sell	Dispose S	No	Yes	30.0216	8,015	240.62 k	14,863
5 Feb 25	Alan J Russell	Common Stock	Option exercise	Acquire M	No	No	0.18	8,015	1.44 k	22,878
5 Feb 25	Alan J Russell	Stock Option Common Stock	Option exercise	Dispose M	No	No	0.18	8,015	1.44 k	1,348,765
5 Feb 25	Koch Kevin	Common Stock	Sell	Dispose S	No	Yes	30.0252	8,636	259.30 k	14,478

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Scotiabank Initiates Coverage On Edgewise Therapeutics with Sector Outperform Rating, Announces Price Target of $50

Scotiabank analyst Louise Chen initiates coverage on Edgewise Therapeutics (NASDAQ:EWTX) with a Sector Outperform rating and announces Price Target of $50.

RBC Capital Reiterates Outperform on Edgewise Therapeutics, Maintains $56 Price Target

RBC Capital analyst Leonid Timashev reiterates Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and maintains $56 price target.

Stifel Initiates Coverage On Edgewise Therapeutics with Hold Rating, Announces Price Target of $30

Stifel analyst James Condulis initiates coverage on Edgewise Therapeutics (NASDAQ:EWTX) with a Hold rating and announces Price Target of $30.

Edgewise Therapeutics Announces 2025 Priorities, Progress In Muscular Dystrophy And Cardiac Therapies; Seeks Completion Of GRAND CANYON Recruitment For Becker Trials In Q1; Targets Phase 2 FDA Feedback On CANYON In H1; Plans Phase 3 For Duchenne

Evercore ISI Group Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $50

Press releases

From Benzinga Pro

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

– Completed enrollment of the GRAND CANYON global pivotal study of sevasemten in Becker muscular dystrophy (Becker) – – Announced positive top-line results from Phase 2 CANYON trial of sevasemten in Becker – – On

Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development

- Robert Blaustein, M.D., Ph.D. appointed as Chief Development Officer (CDO) - - Behrad Derakhshan, Ph.D. promoted to Chief Operating Officer (COO) - Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle

Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025

Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced that Kevin Koch, Ph.D, President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan

Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.